Karyopharm Therapeutics Inc share price logo

Karyopharm Therapeutics Inc

NASDAQ: KPTI

Small Cap

$8.77

+0.46

(+5.54%)

as on

Karyopharm Therapeutics Inc Stock Performance

as on May 2, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $8.25
    $8.83
    downward going graph

    5.93%

    Downside

    0.68%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.65
    $10.99
    downward going graph

    58.38%

    Downside

    25.31%

    Upside

    downward going graph

Karyopharm Therapeutics Inc share price movements today

Previous Close
$8.31
Open
$8.35
Volume
388.6K
Day's Low - High
$8.25 - $8.83
52 Week Low - High
$3.65 - $10.99

Karyopharm Therapeutics Inc Historical Returns

1 Month Return
+ 48.9 %
3 Month Return
+ 38.99 %
1 Year Return
+ 19.16 %
3 Year Return
-83.67 %
5 Year Return
-93.74 %

Karyopharm Therapeutics Inc Stock Fundamentals & Key Indicators

Check Karyopharm Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$197.7M

EPS (TTM)

-4.7767

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

-0.15

EBITDA

-90.4M

Revenue (TTM)

146.1M

Profit Margin

-134.21%

Return On Equity TTM

-891.05%

Karyopharm Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Karyopharm Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Karyopharm Therapeutics Inc image
Karyopharm Therapeutics Inc
BUY$197.7M-93.74%NA-134.21%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$41.3B110.54%77.5712.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$108.7B94.28%27.9332.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$32.7BNA118.495.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.1B45.73%17.2729.65%

Stock Returns calculator for Karyopharm Therapeutics Inc Stock including INR - Dollar returns

The Karyopharm Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Karyopharm Therapeutics Inc investment value today

Current value as on today

₹1,33,795

Returns

₹33,795

(+33.8%)

Returns from Karyopharm Therapeutics Inc Stock

₹19,158 (+19.16%)

Dollar Impact

₹14,638 (+14.64%)

Analyst Recommendation on Karyopharm Therapeutics Inc Stock

Based on 13 analysts

BUY

84.62%

Buy

15.38%

Hold

0.00%

Sell

Based on 13 analysts, 84.62% of analysts recommend a 'BUY' rating for Karyopharm Therapeutics Inc. Average target price of $12.33

Karyopharm Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Karyopharm Therapeutics Inc.

What analysts predicted

28.87%UPSIDE

Target Price

$12.33

Current Price

$8.77

Analyzed by

13 Analysts

Target

$12.33

Karyopharm Therapeutics Inc target price $12.33, a slight upside of 28.87% compared to current price of $8.77. According to 13 analysts rating.

Karyopharm Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Karyopharm Therapeutics Inc Stock has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-14% versus previous 30 day period

Karyopharm Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
36
33
33
42
38
30
30
37
44
34
Gross Profit
35
32
31
41
37
29
28
36
41
32
Operating Income
-31
-37
-33
-28
-26
-31
-33
-24
-15
-17
EBITDA
-28
-35
-31
32
-20
-19
-12
-25
-22
-17
Interest Expense
6
6
5
8
11
11
10
11
11
12
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-34
-41
-37
23
-32
-30
-23
-37
-33
-102
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-34
-41
-37
23
-32
-30
-23
-37
-33
-102
Net Profit Margin
-95.83%
-123.97%
-112.79%
55.61%
-82.70%
-100.78%
-78.17%
-98.22%
-75.21%
-299.89%

Karyopharm Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
1
30
40
108
209
157
146
145
146
Gross Profit
0
1
-131
38
105
206
151
141
139
140
Operating Income
-110
-130
-179
-189
-171
-98
-142
-129
-119
-90
EBITDA
-110
-129
-175
-182
-167
-96
-139
-118
-38
-90
Interest Expense
1
1
2
15
27
26
24
23
37
45
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-109
-128
-178
-199
-195
-123
-164
-142
-76
-195
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-109
-128
-178
-199
-196
-124
-165
-143
-76
-196
Net Profit Margin
-71153.90%
-8036.39%
-588.10%
-488.08%
-181.59%
-59.14%
-105.23%
-97.99%
-52.62%
-134.21%

Karyopharm Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-41
-37
23
-32
-30
-23
-37
-33
-102
Operating Cash Flow
-18
-43
-38
-19
-25
-38
-18
-5
-11
Investing Cash Flow
26
21
51
7
14
15
18
4
5
Financing Cash Flow
0
-
40
-
0
-
0
-
29
Change in Cash
8
-21
53
-11
-10
-23
0
-1
22

Karyopharm Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-128
-178
-199
-196
-124
-165
-143
-76
-196
Operating Cash Flow
-73
-159
-190
-160
-107
-149
-92
-127
-75
Investing Cash Flow
17
-107
78
-53
141
-104
7
95
43
Financing Cash Flow
75
316
124
172
73
193
1
41
30
Change in Cash
19
49
11
-41
108
-60
-83
9
-1

Global Institutional Holdings in Karyopharm Therapeutics Inc

Funds
Holdings
Ikarian Capital, LLC
2.42%
Group One Trading, LP
0.37%
Eversept Partners, LLC
2.97%
Soleus Capital Management, L.P.
1.95%
Citadel Advisors Llc
2.38%
See all

Karyopharm Therapeutics Inc News & Key Events

    Insights on Karyopharm Therapeutics Inc

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, KPTI has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 1 month, KPTI stock has moved up by 48.9%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Karyopharm Therapeutics Inc has experienced a drawdown of -84.0%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 71.3%

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 44.04M → 34.07M (in $), with an average decrease of 22.6% per quarter

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, -33.12M → -102.19M (in $), with an average decrease of 208.5% per quarter

    About Karyopharm Therapeutics Inc

    Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
    OrganisationKaryopharm Therapeutics Inc
    Headquarters85 Wells Avenue, Newton, MA, United States, 02459-3298
    IndustryBiotechnology
    CEOMr. Richard A. Paulson M.B.A.
    E-voting on sharesClick here to vote

    Key Management of Karyopharm Therapeutics Inc

    Name

    Title

    Ms. Lori A. Macomber CPA

    EVP, CFO & Treasurer

    Mr. James Accumanno J.D.

    Chief Compliance Officer

    Ms. Lisa DiPaolo

    Executive VP & Chief Human Resource Officer

    Mr. Brendan Twohig Strong

    Senior Vice President of Investor Relations

    Mr. Michael J. Mano J.D.

    Executive VP, Chief Legal Officer & Secretary

    Mr. Richard A. Paulson M.B.A.

    President, CEO & Director

    Mr. Stuart Poulton

    Executive VP & Chief Development Officer

    Dr. Reshma Rangwala M.D., Ph.D.

    Executive VP, Chief Medical Officer & Head of Research

    Dr. Sharon Shacham M.B.A., Ph.D.

    Co-Founder & Chairman of Scientific Advisory Board

    Ms. Kristin Abate

    VP, Chief Accounting Officer & Assistant Treasurer

    FAQs

    What is Karyopharm Therapeutics Inc share price today?

    Karyopharm Therapeutics Inc share price today is $8.77 as on at the close of the market. Karyopharm Therapeutics Inc share today touched a day high of $8.83 and a low of $8.25.

    What is the 52 week high and 52 week low for Karyopharm Therapeutics Inc share?

    Karyopharm Therapeutics Inc share touched a 52 week high of $10.99 on and a 52 week low of $3.65 on . Karyopharm Therapeutics Inc stock price today i.e. is closed at $8.77,which is 20.20% down from its 52 week high and 140.25% up from its 52 week low.

    What is Karyopharm Therapeutics Inc's market capitalisation today?

    Karyopharm Therapeutics Inc market capitalisation is $0.00T as on .

    How to invest in Karyopharm Therapeutics Inc Stock (KPTI) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Karyopharm Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Karyopharm Therapeutics Inc Shares that will get you 0.1710 shares as per Karyopharm Therapeutics Inc share price of $8.77 per share as on May 2, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Karyopharm Therapeutics Inc Stock (KPTI) from India?

    Indian investors can start investing in Karyopharm Therapeutics Inc (KPTI) shares with as little as ₹94.91 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹949.10 in Karyopharm Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Karyopharm Therapeutics Inc share’s latest price of $8.77 as on May 2, 2026 at 1:29 am IST, you will get 1.1403 shares of Karyopharm Therapeutics Inc. Learn more about fractional shares .

    What are the returns that Karyopharm Therapeutics Inc has given to Indian investors in the last 5 years?

    Karyopharm Therapeutics Inc stock has given -93.74% share price returns and 28.51% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?